Developmental aspects of metabolic syndrome in children under treatment with gastrointestinal lipase inhibitors
DOI:
https://doi.org/10.52692/1857-0011.2024.1-78.11Keywords:
metabolic syndrome, children, obesity, hypertensionAbstract
Introduction. Alongside the increasing trends in obesity rates, there is a documented rise in the prevalence of metabolic syndrome (MetS) in children, dictating that each component of MetS should be identified as early as possible;and the treatment goal consists of reducing obesity, managing metabolic complications, insulin resistance, and also addressing hypertension (HTN).Aim of the study. To determine risk factors, the role of certain proinflammatory markers (TNF α, hs-CRP), and adipokines (leptin, adiponectin) in the onset of MetS in children and their evolution under treatment with gastrointestinal lipase inhibitors (GLI). Material and methods. The presented results were obtained as part of a project within the State Program 2020-2023 titled “Evolutionary Aspects of Metabolic Syndrome in Children Under Treatment with Gastrointestinal Lipase Inhibitors”, project number 20.80009.8007.33. The study included 57 children with MS (IDF, 2007). Depending on the pharmacological therapy associated with non-pharmacological treatment, the children in the research were divided into 3 groups: Group I- 23 children who received orlistat (orlip) - GLI, Group II - 15 children who received Angiotensin Converting Enzyme Inhibitors (ACEIs), and Group III - 19 children who received both GLI and ACEIs. The control group consisted of 50 normotensive and normal-weight children of similar age (gender ratio: 1:1). Risk factors, body mass index (BMI), waist circumference (WC), blood pressure values, total cholesterol (TC), LDL-C, HDL-C, triglycerides (TG), basal glycemia (BG), serum insulin, TNFα, hs-CRP, leptin, and adiponectin were analyzed initially and at the 3-month interval.The study protocol was approved by the Medical Ethics Committee of the Institute of Cardiology, Republic of Moldova (minutes no.2 dated February 20, 2020).Results: The majority of children in the study had a history of hereditary aggravated HTN and obesity, were sedentary or moderately sedentary, and had poor dietary habits. Among the components of MetS (IDF, 2007) associated with abdominal obesity, the following predominated: hypertension in 38 (66.7%) children, hypertriglyceridemia - 32 (56.1%%) children, increased basal blood glucose (BG) - 17(29.8%) children and hypo-HDL-C - 11 (19.3%) children. BMI at the 3-month interval from the initiation of medication decreased most significantly in group I (-4.025±1.267 kg/ m2), followed by group II (-3.33±0.972 kg/m2), and III (-3.046±0.840 kg/m2). WC decreased most notably in group III (-10.63±3.732 cm) compared to group II (-9.167±1.783 cm) and group I (-4.700±2.352 cm). Similar trends were observed for blood pressure values: group III (-18.75±1.897 mm Hg) vs group II (-12.167±1.359 mm Hg) vs group I (-3.900±4.613 mm Hg). LDL-C decreased essentially in group II (-0.46±0.211 mmol/l), while TG decreased in group III (-0.77±0.325 mmol/l) and II (-0.53±0.112 mmol/l). HDL-C increased by +0.60±0.274 mmol/l in group I, by +0.15±0.066 mmol/l in group II, and by +0.12±0.031 mmol/l in group III. Serum insulin decreased predominantly in group III (-9.36±4.53 µU/ mL). Similar trends were observed for BG (group III -1.24±0.322 mmol/l). TNF α decreased most significantly in group III (-2.65±0.911 pg/ml) compared to group I (-1.24±0.508 pg/ml) and group II (-1.61±1.018 pg/ml). hs-CRP decreased mainly in group I (-0.69±0.785 mg/l) and group II (-0.74±0.593 mg/l) compared to group III (-0.42±0.617 mg/l). Leptin values decreased significantly in all study groups at the 3-month interval from the initiation of medication (group I by-8.80±3.64 ng/ml, group II by -10.92±4.084 ng/ml, group III by -9.75±6.172 ng/ml). Adiponectin values increased by+1.83±1.087 µg/L in group III of the study.Conclusion: In combination with a calorie-restricted diet, regular physical exercise, and behavioral modifications, treatment with ILG and ACEIs in children with MetS in the study contributed to a decrease in the degree of obesity, blood pressure values, and normalization of the lipid and glucose profile, respectively. Additionally, it highlighted both the importance of prevention, early detection, and management of obesity, as well as the causal link between obesity, hypertension, and chronic inflammation.
References
Orsini F., D’Ambrosio Floriana A. S., Ricciardi R., Calabrò G. E. Epidemiological Impact of Metabolic Syndrome in Overweight and Obese European Children and Adolescents: A Systematic Literature Review. Nutr., 2023; 15(18), 3895.
World Health Organization. Obesity and Overweight. 2021. Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
Reisinger, C., Nkeh-Chungag, B.N., Fredriksen,P.M. et al. The prevalence of pediatric metabolic syndrome—a critical look on the discrepancies between definitions and its clinical importance. Int J Obes., 2021; 45; 12–24.
Al-Hamad D, Raman V. Metabolic Syndrome in children and adolescents. Transl. Pediatr., 2017; 6 (4): 397-407.
Bitew, Z.W., Alemu, A., Ayele, E.G. et al. Metabolic syndrome among children and adolescents in low and middle income countries: a systematic review and meta-analysis. Diabetol Metab Syndr., 2020;12, 93.
Gregory J.W. Prevention of Obesity and Metabolic Syndrome in Children. Front. Endocrinol., 2019; 10:669.
Zimmet P., Alberti KG., Kaufman F, et al. IDF Consensus Group. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diab., 2007; 8(5): 299-306.
Peri H. Fk. et al. Lifestyle genomics and the metabolic syndrome: A review of genetic variants that influence response to diet and exercise interventions. F. Sci. and Nut., 2019, vol 59, 2028-2039.
Koskinen et al. Childhood Age and Associations Between Childhood Metabolic Syndrome and Adult Risk for Metabolic Syndrome, Type 2 Diabetes Mellitus and Carotid Intima Media Thickness: The International Childhood Cardiovascular Cohort Consortium. J. Am. Heart Assoc., 2017; 6(8), e005632.
Agirbasli, M. Tanrikulu A.M., Berenson G.S. Metabolic Syndrome: Bridging the gap from childhood to adulthood. Cardiovasc. Ther., 2016; 34(1), 30–36.
Zhou M, Shao J, Wu CY, et al. Targeting BCAA Catabolism to Treat Obesity-Associated Insulin Resistance. Diabetes., 2019; 68(9):1730-1746.
Codazzi V., Frontino G., Galimberti L., Giustina A., Petrelli A. Mechanisms and risk factors of metabolic syndrome in children and adolescents. Endocr., 2024; 84(1):16-28.
Magge Sh. N., Goodman E., et all. The Metabolic Syndrome in Children and Adolescents: Shifting the Focus to Cardiometabolic Risk Factor Clustering. Pediatr., 2017; 140 (2): e20171603. 10.1542/ peds.2017-1603
Torres S. et al. Adipose tissue inflammation and metabolic syndrome. The proactive role of probiotics. Eur. J. Nutr., 2019; 58(1), 27–43.
Vassilopoulou E. et al. Adipokines and C-reactive protein as indicators of MetS presence in obese Greek children: The Healthy Growth Study. Toxicol. Rep., 2021 (8), 1645–1650.
Cura-Esquivel et al. Metabolic, inflammatory and adipokine differences on overweight/obese children with and without metabolic syndrome: A cross- sectional study. PLoS One, 2023; 18(3), e0281381.
Fahed G., et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int. J. Mol. Sci., 2022; 23(2), 786.
Yoojin L. Chu., Young-Jun R. Metabolic Syndrome in children and adolescents. Ewha Med J., 2022; 45(4):e13.
Nigro, E., et al. Adiponectin profile and Irisin expression in Italian obese children: Association with insulin-resistance. Cytokine., 2017; 94: 8-13.
Orlando, A.; Nava, E.; Giussani, M.; Genovesi,S. Adiponectin and Cardiovascular Risk. From Pathophysiology to Clinic: Focus on Children and Adolescents. Int. J. Mol. Sci., 2019; (20): 3228.
Clemente-Suárez VJ., Martín-Rodríguez A., Redondo- Flórez L., López-Mora C., Yáñez-Sepúlveda R., Tornero-Aguilera JF. New Insights and Potential Therapeutic Interventions in Metabolic Diseases. Int. J. of Mol. Sci., 2023; 24(13):10672.
Styne DM., Arslanian SA., Connor EL., Farooqi IS., Hassan Murad M., Silverstein JH., et al. Pediatric obesity—assessment, treatment, and prevention: an endocrine society clinical practice guideline. J Clin. Endoc. Metab., 2017;102(3):709-75.
Maahs D., de Serna DG., Kolotkin RL., Ralston S., Sandate J., Qualls C., et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr. Pract., 2006; 12(1):18.
Nikniaz Z., Nikniaz L., Farhangi M. A., Mehralizadeh H., & Salekzamani, S. Effect of Orlistat on anthropometrics and metabolic indices in children and adolescents: a systematic review and meta-analysis. BMC endocrine disorders, 2023; 23(1):142.
Madhurantakam Sa., et al. Metabolic Syndrome— An Emerging Constellation of Risk Factors: Electrochemical Detection Strategies. Sensors (Basel). 2020; 20(1): 103.
Friend A., Craig L., Turner S. The prevalence of metabolic syndrome in children: a systematic review of the literature. Metab. Syndr. Related Disord., 2013; 11(2):71–80.
Wan Mahmud Sabri, W. M. N., Mohamed, R. Z., Yaacob, N. M., Hussain, S. Prevalence of Metabolic Syndrome and its Associated Risk Factors in Pediatric Obesity. J. of the ASEAN Fed. of End. Soc., 2022; 37(1): 24–30.
Cojocari S., Mătrăgună N., Bichir-Thoreac L. Sindromul metabolic la copii: factori de risc, particularități de diagnostic și tratament. Buletinul Academiei de Științe a Moldovei. Științe Medicale, 2023; 1(75):73-86.
Prateek K. P. Metabolic syndrome in children: definition, risk factors, prevention and management-a brief overview. Ped. Oncall J. 2019; 16(3): 67-72.
Tagi V. M., Samvelyan S., Chiarelli F. Treatment of Metabolic Syndrome in Children. Horm. Res. Paediatr., 2020; 93 (4): 215–225.
Gaillard R., Steegers EAP., Duijts L., et al. Childhood cardiometabolic outcomes of maternal obesity during pregnancy: the generation R study. Hypert., 2014; 63: 683–91.
Yang Z., Li Y., Dong B., Gao D., Wen B., Ma J. Relationship between parental overweight and obesity and childhood metabolic syndrome in their offspring: result from a cross-sectional analysis of parent-offspring trios in China. BMJ Open. 2020; 10(12): e036332.
Kopec G., Shekhawat P.S., Mhanna M.J. Prevalence of diabetes and obesity in association with prematurity and growth restriction. Diabetes Metab. Syndr. Obes., 2017; 10:285-295.
Heidemann LA., Procianoy RS., Silveira RC. Prevalence of metabolic syndrome-like at 2 years of corrected age in very low birth weight preterm infants and associated factors. J. Pediatr. (Rio J)., 2019; 95:291–297.
Cheshmeh S., Nachvak SM., Hojati N., Elahi N., Heidarzadeh-Esfahani N., Saber A. The effects of breastfeeding and formula feeding on the metabolic factors and the expression level of obesity and diabetes- predisposing genes in healthy infants. Physiol. Rep., 2022;10(19):e15469.
De Carvalh R. B. N., De Sousa R. N., Guimarães M. R. et al. Risk factors associated with the development of metabolic syndrome in children and adolescents. Acta Paul Enferm., 2016; 29(4):439-45.
Kara L. Marlatt et al. Breakfast and fast food consumption are associated with selected biomarkers in adolescents. Prev. Med. Reports., 2016; 3: 49-52.
Ramírez-López G., Flores-Aldana M., Salmerón J. Associations between dietary patterns and metabolic syndrome in adolescents. Sal. Púb. de México, 2019; 61(5): 619-628.
Pervanidou P., Chrousos G. P. Stress and obesity/ metabolic syndrome in childhood and adolescence. IJPO, 2011; (6): 21-28.
Hoveling, L.A., Liefbroer, A.C., Bültmann, U. et al. Socioeconomic differences in metabolic syndrome development: examining the mediating role of chronic stress using the Lifelines Cohort Study. BMC Public Health., 2022; (22): 261.
Díaz-Ortega J. L., Yupari-Azabache I. L., Caballero Vidal J., A., et al. Nelson. Criteria in the Diagnosis of Metabolic Syndrome in Children: A Scoping Review. Diab. Metab. Syndr. Obes., 2023; 16: 3489–3500.
Zebenay W.B., Ayinalem A., Ermias G. A., Zelalem T., Anmut A., Teshager W. Metabolic syndrome among children and adolescents in low and middle income countries: a systematic review and meta-analysis. Diabetol. Metab. Syndr., 2020; 12:93.
Pelin, A.M.; Mătăsaru, S. Metabolic syndrome in obese children and adolescents. Rev. Med. Chir. Soc. Med. Nat. Iasi., 2012; 116: 957–961.
Jankowska A., Brzeziński M., Romanowicz- Sołtyszewska A., Szlagatys Sidorkiewicz A. Metabolic Syndrome in Obese Children-Clinical Prevalence and Risk Factors. Int. J. Environ. Res. Public Health., 2021: 18; 1060.
Smetanina N., Valickas R., Vitkauskiene A., Albertsson-Wikland K., Verkauskienė R. Prevalence of Metabolic Syndrome and Impaired Glucose Metabolism among 10- to 17-Year-Old Overweight and Obese Lithuanian Children and Adolescents. Obes. Facts., 2021; (14): 271–282.
González-Jiménez E., Montero-Alonso M.A., Schmidt-RioValle J, García-García C.J., Padez C. Metabolic syndrome in Spanish adolescents and its association with birth weight, breastfeeding duration, maternal smoking, and maternal obesity: A cross- sectional study. Eur. J. Nutr., 2015; (54): 589–597.
Szabelska-Zakrzewska K., Durko A., Socha-Banasiak A., Majewsk, M., Kolejwa M., Kazanek-Zasada J., Czkwianianc E. Metabolic syndrome in overweight or obese children and adolescents based on own material Abstract Key words. Dev. Period Med., 2018; 22: 351– 357.
Martino F., Pannarale G., Puddu P.E., Colantoni C., Zanoni C., Martino E., Torromeo C., Paravati,V., Perla F.M., Barillà F. Is it possible a new definition of metabolic syndrome in childhood? Eur. Rev. Med. Pharmacol. Sci., 2015; 19: 4324–4331.
Paley CA., Johnson MI. Abdominal obesity and metabolic syndrome: exercise as medicine? BMC Sports Sci Med Rehabil., 2018;10:7.
Pascu BM., Miron VD., Matei ER., Craiu M. Laboratory Findings in Children with Excess Body Weight in Romania. Medicina (Kaunas). 2023; 59(2):319.
Tragomalou A., Paltoglou G., Manou M., Kostopoulos IV., Loukopoulou S., Binou M., Tsitsilonis OE., Bacopoulou F., Kassari P., Papadopoulou M., et al. Non-Traditional Cardiovascular Risk Factors in Adolescents with Obesity and Metabolic Syndrome May Predict Future Cardiovascular Disease. Nutr., 2023; 15(20):4342.
Shin SH., Lee YJ., Lee YA., Kim JH., Lee SY., Shin CH. High-Sensitivity C-Reactive Protein Is Associated with Prediabetes and Adiposity in Korean Youth. Metab Syndr Relat Disord., 2020;18(1):47-55.
Gunturiz Albarracín M. L., Forero Torres A. Y. Adiponectin and Leptin Adipocytokines in Metabolic Syndrome: What Is Its Importance? Dubai Diab. End. J. 2020; 26 (3): 93–102.
GhadgeA.A., KhaireA.A. Leptin asapredictive marker for metabolic syndrome. Cyt., 2019;121:154735.
Madeira I.et al. Leptin as a predictor of metabolic syndrome in prepubertal children. Arch. End. Metab., 2017; 61 (1).
Nappo A., González-Gil EM., Ahrens W., Bammann K., Michels N., Moreno LA., Kourides Y. Analysis of the association of leptin and adiponectin concentrations with metabolic syndrome in children: Results from the IDEFICS study. Nutr Metab Cardiovasc Dis., 2017; 27(6):543-551.
Coelho M., Oliveira T., Fernandes R. Biochemistryof adipose tissue: an endocrine organ. Arch Med Sci., 2013; 9(2):191-200.
Tkachenko O., Polishchuk I., Gorchakova N., at al. Metabolic Syndrome and Lipid Metabolism Disorders: Molecular and Biochemical Aspects. Acta Facult. Med. Naiss. 2020; 37(1):5-22
Klünder-Klünder M., Flores-Huerta S., García- Macedo, R. et al. Adiponectin in eutrophic and obese children as a biomarker to predict metabolic syndrome and each of its components. BMC Pub. Health., 2013; (13):88.
Nur Aisiyah W. Metabolic syndrome, HOMA-IR and adiponectin in obese adolescents. Med. J., 2023; 1(1).
DeBoer MD. Assessing and Managing the Metabolic Syndrome in Children and Adolescents. Nutrients. 2019; 11(8):1788.
World Health Organization. WHO Guidelines Approved by the Guidelines Review Committee. In WHO Guidelines on Physical Activity and Sedentary Behaviour; World Health Organization: Geneva, Switzerland, 2020.
Moghetti P., Bacchi E., Brangani C., Donà S., Negri C. Metabolic effects of exercise. Front Horm Res., 2016; 47:44–57.
Fornari E., Maffeis C. Treatment of metabolic syndrome in children. Front. in End., 2019;10:702.
Escalante Y., Saavedra JM., García-Hermoso A., Domínguez AM. Improvement of the lipid profile with exercise in obese children: a systematic review. Prev Med., 2012;54:293–301.
Farpour-Lambert NJ., Aggoun Y., Marchand LM., Martin XE., Herrmann FR., Beghetti M. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J Am Coll Cardiol., 2009;54:2396–406.
Stoner L., Rowlands D., Morrison A., Credeur D., Hamlin M., Gaffney K., et al. Efficacy of exercise intervention for weight loss in overweight and obese adolescents: meta-analysis and implications. Sports Med., 2016;46:1737–51.
Castro-Barquero S., Ruiz-León A.M., Sierra-Pérez M., Estruch R., Casas R. Dietary Strategies for Metabolic Syndrome: A Comprehensive Review. Nut., 2020; 12, 2983.
Flynn JT., Kaelber DC., Baker-Smith CM., Blowey D., Carroll AE., Daniels SR, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics., 2017;140(3):e20171904.
Fornari E., Maffeis C. Treatment of Metabolic Syndrome in Children. Front End., (Lausanne). 2019; 15 (10): 702.
Tian-Tian L., Xiao-Tian L., Qing-Xi Ch.Y. Shi: Lipase Inhibitors for Obesity: A Review. Biomed Pharmacother., 2020;128:110314.
Kelly L.M., Renee M. F. Treatment of Obesity in Children and Adolescents. J. Pediatr. Pharmacol Ther., 2012; 17 (1): 45–57.
Chanoine J.P., Hampl S., Jensen C., Boldrin M., Hauptman J. Effect of Orlistat on Weight and Body, Composition in Obese Adolescents. A Randomized Controlled Trial. JAMA, 2005; 293:232.
Rajjo T., Mohammed K., Alsawas M., Ahmed AT., Farah W., Asi N., Almasri J, Prokop LJ, Murad MH. Treatment of Pediatric Obesity: An Umbrella Systematic Review. J Clin Endocrinol Metab., 2017;102(3):763-775.
Mead E., Atkinson G., Richter B., Metzendorf MI., Baur L., Finer N., Corpeleijn E., O’Malley C., Ells LJ. Drug interventions for the treatment of obesity in children and adolescents. Cochr. Database Syst Rev., 2016; 29;11(11).
Yu C.C., Li A.M., Chan C.O., Chook P., Kam J.T., et al. Orlistat improves endothelial function in obese adolescents: A randomized trial. J. Paediatr. Child. Health Drug., 2013; 49, 969–975.
Downloads
Published
License
Copyright (c) 2024 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
